Search results for "Disease Presentation"

showing 4 items of 4 documents

Bleeding symptoms at disease presentation and prediction of ensuing bleeding in inherited FVII deficiency.

2012

SummaryIndividuals with inherited factor VII (FVII) deficiency display bleeding phenotypes ranging from mild to severe, with 30% of patients having always been asymptomatic (non-bleeding). In 626 FVII-deficient individuals, by analysing data from the International Factor VII (IF7) Registry and the Seven Treatment Evaluation Registry (STER), we determined whether bleeding type at disease presentation and FVII coagulant activity (FVIIc) predict ensuing bleeds. At disease presentation/diagnosis, 272 (43.5%) individuals were non-bleeding, 277 (44.2%) had minor bleeds, and 77 (12.3%) had major bleeds. During a median nine-year index period (IP) observation, 87.9% of non-bleeding individuals at p…

RegistrieMalePediatricsFactor VII DeficiencyInternational CooperationAsymptomatic individual030204 cardiovascular system & hematologychemistry.chemical_compound0302 clinical medicineRetrospective StudieAge FactorRegistriesYoung adultChildClinical Trials as TopicHematologyFactor VIIAge FactorsHematologyFactor VIIMiddle AgedPhenotypeTreatment OutcomeChild PreschoolFemalePresentation (obstetrics)medicine.symptomHumanAdultQuality ControlRiskmedicine.medical_specialtyAdolescentHemorrhageAsymptomaticMajor bleed03 medical and health sciencesYoung AdultInternal medicinemedicineHumansRetrospective StudiesModels Statisticalbusiness.industryMinor bleedInfantRetrospective cohort studychemistryDisease PresentationRelative riskbusiness030215 immunologyThrombosis and haemostasis
researchProduct

Real-world data confirm the effectiveness of caplacizumab in acquired thrombotic thrombocytopenic purpura

2020

Abstract Acquired thrombotic thrombocytopenic purpura (aTTP) is a rare but life-threatening condition. In 2018, the nanobody caplacizumab was approved for the treatment of adults experiencing an acute episode of aTTP, in conjunction with plasma exchange (PEX) and immunosuppression for a minimum of 30 days after stopping daily PEX. We performed a retrospective, observational analysis on the use of caplacizumab in 60 patients from 29 medical centers in Germany during acute disease management. Caplacizumab led to a rapid normalization of the platelet count (median, 3 days; mean 3.78 days). One patient died after late treatment initiation due to aTTP-associated complications. In 2 patients with…

Adultmedicine.medical_specialtyExacerbationmedicine.medical_treatmentThrombotic thrombocytopenic purpuraMedizin030204 cardiovascular system & hematology03 medical and health sciences0302 clinical medicineFibrinolytic AgentsInternal medicinemedicineHumansRetrospective StudiesAcquired Thrombotic Thrombocytopenic PurpuraPurpura Thrombotic Thrombocytopenicbusiness.industryImmunosuppressionRetrospective cohort studyHematologySingle-Domain Antibodiesmedicine.diseasePurpuraDisease PresentationCardiovascular and Metabolic Diseases030220 oncology & carcinogenesisCaplacizumabmedicine.symptombusiness
researchProduct

Congenital Hepatic Fibrosis

2005

The disease presentation of autosomal recessive polycystic kidney disease (OMIM #263200, ARPKD) is highly variable and includes polycystic kidneys, pulmonary hypoplasia, and congenital hepatic fibrosis. The authors report an unusual case of ARPKD presenting with hepatosplenomegaly and cytopenia mimicking acute leukemia.

Liver CirrhosisMalePathologymedicine.medical_specialtyAdolescentPancytopeniaHepatosplenomegalyurologic and male genital diseasesPulmonary hypoplasiahemic and lymphatic diseasesmedicineHumanscytopeniaPolycystic Kidney Autosomal RecessivesplenomegalyCytopeniaAcute leukemiapolycystic kidney diseasebusiness.industryHematologymedicine.diseasePancytopeniaeye diseasesfemale genital diseases and pregnancy complicationsAutosomal Recessive Polycystic Kidney DiseaseOncologyDisease PresentationPediatrics Perinatology and Child HealthCongenital hepatic fibrosismedicine.symptomTomography X-Ray ComputedbusinessHepatomegalyJournal of Pediatric Hematology/Oncology
researchProduct

The problems and promises of research into human immunology and autoimmune disease

2012

Translational research in autoimmunity is hampered by a number of hurdles, including a lack of knowledge regarding initiating and pathologically relevant autoantigens, the low frequency of autoreactive pathogenic B and T cells, difficulty in accessing the affected tissue, differences between self-reactive and pathogen-specific lymphocytes, a lack of etiologically relevant preclinical animal models and the heterogeneity of disease presentation. Given the need for biomarkers and new therapeutics, it is imperative that these hurdles be surmounted.

T-LymphocytesTranslational researchmedicine.disease_causeAutoantigensGeneral Biochemistry Genetics and Molecular BiologyAutoimmunityAutoimmune DiseasesTranslational Research BiomedicalMiceRisk FactorsmedicineAnimalsHumansLack of knowledgeGenetic Predisposition to DiseaseAutoimmune diseaseB-Lymphocytesbusiness.industryGeneral Medicinemedicine.diseaseDisease Models AnimalDisease PresentationImmunologybusinessBiomarkersGenome-Wide Association Study
researchProduct